DeLaney William J III

SEC source: 0000100885-19-000225 · edgardoc.xml · derivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 261 shares

Expires not disclosed

F1 · security: Distribution ratio for Phantom Stock Units is 1:1.

F2 · derivative.exercise_date: Phantom Stock Units are payable in cash only commencing at retirement.

F2 · derivative.expiration_date: Phantom Stock Units are payable in cash only commencing at retirement.

SEC source: 0001225208-19-012162 · doc4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,883

SEC source: 0000100885-19-000166 · edgardoc.xml · derivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 844

Underlying: Common Stock · 237 shares

Expires not disclosed

F1 · security: Distribution ratio for Phantom Stock Units is 1:1.

F2 · derivative.exercise_date: Phantom Stock Units are payable in cash only commencing at retirement.

F2 · derivative.expiration_date: Phantom Stock Units are payable in cash only commencing at retirement.

SEC source: 0001225208-19-008806 · doc4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,575

SEC source: 0000100885-19-000142 · edgardoc.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 19, 2019.

SEC source: 0000100885-19-000102 · edgardoc.xml · derivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 607

Underlying: Common Stock · 236 shares

Expires not disclosed

F1 · security: Distribution ratio for Phantom Stock Units is 1:1.

F2 · derivative.exercise_date: Phantom Stock Units are payable in cash only commencing at retirement.

F2 · derivative.expiration_date: Phantom Stock Units are payable in cash only commencing at retirement.

SEC source: 0001104659-19-015988 · a4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,419

F1 · security: EACH RESTRICTED STOCK UNIT REPRESENTS A CONTINGENT RIGHT TO RECEIVE ONE SHARE OF SANMINA COMMON STOCK.

F2 · shares: THE RESTRICTED STOCK UNITS VEST IN FOUR EQUAL QUARTERLY INSTALLMENTS FROM DATE OF GRANT.

SEC source: 0001225208-19-005536 · doc4.xml · derivative · entry 2

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $.01 Par Value · 2,199 shares

Expires 2019-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Stock option previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Options vested in three equal annual installments on May 1, 2013, May 1, 2014, and May 1, 2015.

SEC source: 0001225208-19-005536 · doc4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-19-004402 · doc4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,056

SEC source: 0000100885-19-000006 · edgardoc.xml · derivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 371

Underlying: Common Stock · 290 shares

Expires not disclosed

F1 · security: Distribution ratio for Phantom Stock Units is 1:1.

F2 · derivative.exercise_date: Phantom Stock Units are payable in cash only commencing at retirement.

F2 · derivative.expiration_date: Phantom Stock Units are payable in cash only commencing at retirement.

SEC source: 0001567619-18-008712 · doc1.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,849

SEC source: 0001567619-19-002845 · doc1.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,784

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 7

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 8,006 shares

Expires 2027-05-11

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 6

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 7,032 shares

Expires 2026-05-04

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 5

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 5,604 shares

Expires 2025-05-06

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 4

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 6,402 shares

Expires 2021-05-07

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 3

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 5,872 shares

Expires 2020-05-09

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · derivative · entry 2

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 4,580 shares

Expires 2019-05-30

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.

SEC source: 0000950138-18-000673 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc. ("Merger"), upon closing of the Merger, each common share of the Issuer was converted into 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 8

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,844

Underlying: Common Stock, $0.01 Par Value · 3,844 shares

Expires 2027-05-11

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 7

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,376

Underlying: Common Stock, $0.01 Par Value · 3,376 shares

Expires 2026-05-04

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 6

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,691

Underlying: Common Stock, $0.01 Par Value · 2,691 shares

Expires 2025-05-06

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 5

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,074

Underlying: Common Stock, $0.01 Par Value · 3,074 shares

Expires 2021-05-07

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 4

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,819

Underlying: Common Stock, $0.01 Par Value · 2,819 shares

Expires 2020-05-09

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · derivative · entry 3

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,199

Underlying: Common Stock, $0.01 Par Value · 2,199 shares

Expires 2019-05-30

F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement.

F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger.

SEC source: 0001567619-18-008712 · doc1.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,648

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-19-002845 · doc1.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,583

F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · shares: Prior to the Merger, the reporting person held Express Scripts restricted stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error.

F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · balance_after: Prior to the Merger, the reporting person held Express Scripts restricted stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error.

SEC source: 0000950138-18-000582 · edgar.xml · derivative · entry 3

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Express Scripts Holding Company Common Stock · 5,464 shares

Expires 2018-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents options that were automatically exercised immediately prior to the expiration of the options.

F3 · price: Grant of Stock Options pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on October 28, 2012, October 28, 2013, and October 28, 2014.

F3 · derivative.exercise_date: Grant of Stock Options pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on October 28, 2012, October 28, 2013, and October 28, 2014.

SEC source: 0000950138-18-000582 · edgar.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,989

F1 · shares: Represents shares tendered to Company to cover payment of exercise price due upon exercise of stock option previously awarded under long-term incentive plan.

SEC source: 0000950138-18-000582 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000100885-18-000234 · edgardoc.xml · derivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81

Underlying: Common Stock · 81 shares

Expires not disclosed

F1 · security: Distribution ratio for Phantom Stock Units is 1:1.

F2 · derivative.exercise_date: Phantom Stock Units are payable in cash only commencing at retirement.

F2 · derivative.expiration_date: Phantom Stock Units are payable in cash only commencing at retirement.

SEC source: 0000950138-18-000369 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,232

F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on May 1, 2019, May 1, 2020, and May 1, 2021.

SEC source: 0001104659-18-018325 · a4.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,527

F1 · security: EACH RESTRICTED STOCK UNIT REPRESENTS A CONTINGENT RIGHT TO RECEIVE ONE SHARE OF SANMINA COMMON STOCK.

F2 · shares: THE RESTRICTED STOCK UNITS VEST IN FOUR EQUAL QUARTERLY INSTALLMENTS FROM DATE OF GRANT.

SEC source: 0000096021-17-000233 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,210

F1 · shares: These shares were withheld upon the vesting of restricted stock units to pay tax withholding obligations.

SEC source: 0000096021-17-000207 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,817

F1 · shares: These shares were withheld upon the vesting of restricted stock units to pay tax withholding obligations.

SEC source: 0000096021-17-000176 · edgar.xml · nonDerivative · entry 3

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 371,667

F3 · shares: These shares were withheld upon the vesting of restricted stock units to pay tax withholding obligations.

SEC source: 0000096021-17-000176 · edgar.xml · derivative · entry 4

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2019-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: Options granted by the Compensation Committee of the company's Board of Directors pursuant to the 2007 Stock Incentive Plan, as amended.

F4 · derivative.exercise_date: Options are fully exercisable.

SEC source: 0000096021-17-000176 · edgar.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,725

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted average sale price per share of the 150,000 shares sold on this date. These shares were sold in multiple transactions at prices ranging from $53.87 to $54.35. The Reporting Person undertakes to provide to Sysco Corporation, any security holder of Sysco Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in the footnote of this Form 4.

SEC source: 0000096021-17-000176 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 526,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000096021-17-000162 · edgar.xml · derivative · entry 3

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2017-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: Options granted by the Compensation Committee of the company's Board of Directors pursuant to the 2007 Stock Incentive Plan, as amended.

F3 · derivative.exercise_date: Options are fully exercisable.

SEC source: 0000096021-17-000162 · edgar.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,725

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted average sale price per share of the 30,000 shares sold on this date. These shares were sold in multiple transactions at prices ranging from $54.58 to $54.88. The Reporting Person undertakes to provide to Sysco Corporation, any security holder of Sysco Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in the footnote of this Form 4.

SEC source: 0000096021-17-000162 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000096021-17-000134 · edgar.xml · derivative · entry 3

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 118,200 shares

Expires 2019-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: Options granted by the Compensation Committee of the company's Board of Directors pursuant to the 2007 Stock Incentive Plan, as amended.

F3 · derivative.exercise_date: Options are fully exercisable.

SEC source: 0000096021-17-000134 · edgar.xml · nonDerivative · entry 2

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,725

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted average sale price per share of the 118,200 shares sold on this date. These shares were sold in multiple transactions at prices ranging from $53.82 to $54.19. The Reporting Person undertakes to provide to Sysco Corporation, any security holder of Sysco Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in the footnote of this Form 4.

SEC source: 0000096021-17-000134 · edgar.xml · nonDerivative · entry 1

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000096021-17-000132 · edgar.xml · derivative · entry 6

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,200

Underlying: Common Stock · 200,000 shares

Expires 2019-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: Options granted by the Compensation Committee of the company's Board of Directors pursuant to the 2007 Stock Incentive Plan, as amended.

F3 · derivative.exercise_date: Options are fully exercisable.

SEC source: 0000096021-17-000132 · edgar.xml · nonDerivative · entry 4

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,725

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000096021-17-000132 · edgar.xml · nonDerivative · entry 3

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 576,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000096021-17-000132 · edgar.xml · derivative · entry 5

DeLaney William J III · CIK 0001384151 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 468,200

Underlying: Common Stock · 81,800 shares

Expires 2019-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: Options granted by the Compensation Committee of the company's Board of Directors pursuant to the 2007 Stock Incentive Plan, as amended.

F3 · derivative.exercise_date: Options are fully exercisable.